Aim Immunotech CEO Thomas Equels buys $6,730 in stock

AIM ImmunoTech Inc. (NYSE:AIM) CEO and President Thomas K. Equels recently acquired 50,000 shares of the company’s common stock, according to a recent regulatory filing. The purchase comes as the stock has declined nearly 60% over the past six months, with InvestingPro data showing analyst price targets ranging from $1.00 to $4.50. The purchase, made on March 5, 2025, was executed at a price of $0.1346 per share, amounting to a total transaction value of $6,730. Following this acquisition, Equels holds a total of 1,858,029 shares in AIM ImmunoTech. The transaction reflects Equels’ continued investment in the company, despite InvestingPro analysis indicating weak financial health with a score of 1.35 out of 5 and a concerning current ratio of 0.75. Get deeper insights into insider trading patterns and 7 additional key ProTips with an InvestingPro subscription.

In other recent news, AIM ImmunoTech Inc. announced that it has received approval from the NYSE American for its compliance plan, allowing the company until June 11, 2026, to meet the exchange’s minimum stockholders’ equity requirements. The company is also advancing its lead product, Ampligen, as a potential vaccine adjuvant for avian influenza, collaborating with Amarex Clinical Research to manage a follow-up investigational new drug application. In a strategic move, AIM ImmunoTech executives have decided to forgo their 2024 cash bonuses to redirect funds toward research and development, particularly focusing on Ampligen. Additionally, during the company’s recent 2024 Annual Meeting of Stockholders, shareholders elected new directors amid a proxy battle, with Nancy K. Bryan and William M. Mitchell receiving the highest votes among company nominees. The shareholders also ratified BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2024. However, a non-binding advisory vote on executive compensation did not pass. These developments highlight AIM ImmunoTech’s ongoing efforts to strengthen its financial and research strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.